{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196513","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.677550+00:00","generated_at":"2026-05-31T10:55:35.380421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Viridian Q2 net loss $65M; THRIVE topline readout on track for Sept 2024; cash $571.4M","bullets":["Net loss of $65.0M in Q2 2024 vs $55.1M Q2 2023; cash balance $571.4M as of June 30, 2024.","THRIVE phase 3 (active TED) topline data for VRDN-001 expected September 2024.","THRIVE-2 (chronic TED) enrollment completed with 188 patients, exceeding 159 target; topline due year-end 2024.","REVEAL-1 and REVEAL-2 phase 3 trials for subcutaneous VRDN-003 to initiate August 2024; topline data H1 2026.","IND for VRDN-006 (FcRn inhibitor) on track for year-end 2024; NHP data for VRDN-008 expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196513","json":"https://secwatch.observer/filing/0001193125-24-196513.json","markdown":"https://secwatch.observer/filing/0001193125-24-196513.md","text":"https://secwatch.observer/filing/0001193125-24-196513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524196513/0001193125-24-196513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524196513/d879446d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:55:35.380421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}